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Background: The 2010 Revisions to the McDonald Criteria have established that dissemination in time (DIT) of
multiple sclerosis (MS) can be demonstrated by simultaneous presence of asymptomatic gadolinium-enhancing and
nonenhancing lesions on a single magnetic resonance imaging (MRI). However, gadolinium-based contrast agents
(GBCAs) have contraindications. Diffusion-weighted imaging (DWI) can detect diffusion alterations in active
inflammatory lesions. The purpose of this study was to investigate if DWI can be an alternative to contrast-enhanced
T1-weighted imaging (CE T1WI) for demonstrating DIT in MS.
Methods: We selected patients with clinically definite MS and evaluated their baseline brain MRI. Asymptomatic
lesions were identified as either hyperintense or nonhyperintense on DWI and enhancing or nonenhancing on CE
T1WI. Fisher’s exact test was performed to determine whether the hyperintensity on DWI was related to the
enhancement on CE T1WI (P < 0.05). The sensitivity, specificity, positive predictive value (PPV), negative predictive value
(NPV), and accuracy of the DWI to predict lesion enhancement were calculated.
Results: Twenty-two patients with 384 demyelinating lesions that were hyperintense on T2-weighted imaging and
more than 3 mm in size were recruited. The diffusion hyperintensity and lesion enhancement were significantly
correlated (P <0.001). The sensitivity, specificity, PPV, NPV and accuracy were 100%, 67.9%, 32.3%, 100% and 72.1%,
respectively.
Conclusions: A hyperintense DWI finding does not necessarily overlap with contrast enhancement. There are many
false positives, possibly representing other stages of lesion development. Although DWI may not replace CE T1WI
imaging to demonstrate DIT due to the low PPV, it may serve as a screening MRI sequence where the use of GBCAs is
a concern.
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The diagnosis of multiple sclerosis (MS) is established
on demonstration of central nervous system (CNS) de-
myelinating lesions with dissemination in space (DIS)
and time (DIT) and exclusion of alternative diagnoses.
The diagnosis can be made on clinical grounds alone,
and magnetic resonance imaging (MRI) findings can
replace objective clinical evidence of one lesion and
one clinical attack once they meet MRI DIS and DIT
criteria. The 2010 Revisions to the McDonald Criteria
simplifies the MRI criteria, and the diagnosis of MS
can be made based on a single MRI scan in some pa-
tients at the clinically isolated syndrome (CIS) stage
[1]. According to criteria developed by Swanton et al.,
DIS can be demonstrated by more than one T2 lesion
in at least two of four CNS areas affected by MS
(periventricular, juxtacortical, infratentorial, and spinal
cord) and DIT can be demonstrated by a new T2
and/or gadolinium-enhancing lesion on follow-up MRI
or by simultaneous presence of asymptomatic gadolin-
ium-enhancing and nonenhancing lesions at any time,
representing demyelinating lesions in different stages
of evolution (the latter proposed by Rovira et al.) [1-4].
Contrast enhancement in demyelinating lesions
and blood–brain barrier (BBB) breakdown on histo-
pathology have been generally regarded as signs of
active perivascular inflammation. However, gadoli-
num-based contrast agents (GBCAs) have contrain-
dications, such as increased risk for developing
nephrogenic systemic fibrosis in patients with acute
or chronic severe renal insufficiency (glomerular fil-
tration rate below 30 mL/min/1.73 m2) and allergy
to GBCAs [5,6]. Besides, in the 2013 Manual of
Contrast Media, the American College of Radiology
states that because it is unclear how GBCAs will
affect the fetus, these agents should be administered
with caution in pregnant women. They should only
be used if their usage is considered critical and the
potential benefits justify the potential risk to the un-
born fetus [6]. In patients with contraindications or
relative contraindications to GBCAs, an alternative
MRI sequence may be needed for early and accurate
diagnosis of MS. Diffusion-weighted imaging (DWI)
has been widely used to diagnose acute ischemic in-
farction and also to detect diffusion alterations in
active inflammatory lesions. Whether it can sub-
stitute for contrast-enhanced T1-weighted imaging
(CE T1WI) to differentiate different features of de-
myelinating disease (e.g., DIT) has yet to be verified.
The purpose of this study was to investigate the
relationship of the signal intensity of demyelinating
lesions on DWI to the status of enhancement on CE
T1WI in baseline brain MRI in patients with clini-
cally definite MS (CDMS).Methods
Study population
From January 2001 to December 2012, patients who
presented with acute CNS symptoms suggestive of de-
myelinating disease in our institutions were recruited in
the cohort of CIS. Patients with final diagnosis of CDMS
made by experienced neurologists after two or more
clinical attacks of CNS demyelinating events and objec-
tive clinical evidence of two or more lesions as defined
by the McDonald Criteria and exclusion of other pos-
sible alternative diseases (such as acute disseminated
encephalomyelitis or neuromyelitis optica) were consi-
dered candidates for this study. The inclusion criteria
also included: (1) age at onset between 15 and 50 years
old; (2) patients’ baseline brain MRI studies performed
within three months of symptom onset; (3) CE T1WI
and DWI included in the MRI protocol; (4) no use of
disease modifying drugs (e.g. interferon) or steroid be-
fore baseline brain MRI examinations to eliminate their
effect on contrast enhancement and edema in demyelin-
ating lesions. Ethical approval for patient recruitment in
our previous study was extended to our present study
by the institutional review board of Tri-Service General
Hospital (TSGH IRB 1-101-05-004). Because this study
was based on retrospective analysis of existing data, no
additional approval was required.
MRI sequences and imaging analysis
The MRI studies were performed on 1.5-T MR scanners.
The brain MRI sequences included spin echo (SE) or fast
spin echo (FSE) T1WI, T2-weighted imaging (T2WI), and
T2-fluid-attenuated inversion recovery (T2-FLAIR) in the
axial plane, T2WI or T2-FLAIR in the sagittal plane, and
CE T1WI in the axial, coronal, and sagittal planes after in-
jection of 0.1 mmol/kg of GBCAs. DWI was acquired with
a single-shot echo planar spin-echo sequence in three
orthogonal directions with a b value of 1000 sec/mm2 and
a baseline image with a b value of 0 sec/mm2. Apparent
diffusion coefficient (ADC) and exponential ADC (eADC)
maps were automatically generated. The DWI was per-
formed prior to administration of GBCAs with an iden-
tical slice thickness (5 mm) and position to T1WI, T2WI,
and T2-FLAIR. The demyelinating lesions were first la-
beled by an experienced neuroradiologist on T2WI and
T2-FLAIR with their sizes being no less than 3 mm for
better delineation on CE T1WI and DWI. An experienced
neurologist reviewed the medical records and then ex-
cluded the symptomatic lesions. The remaining demyelin-
ating lesions were determined as either enhancing or
nonenhancing on CE T1WI. On DWI, ADC and eADC
maps, the signal intensity of the lesions was determined as
either hyperintense, isointense or hyporintense to the sur-
rounding normal-appearing white matter. The area of
perilesional edema, if any, was not evaluated.
Table 1 Classification of the types and subtypes of demyelinating lesions
Lesion type CE T1WI DWI Lesion subtype DWI ADC eADC
I C+ Hyper A Hyper Hypo Hyper
II C+ Iso or hypo
III C– Hyper B Iso, hypo or hyper (T2 T-S) Iso or hyper Iso or hypo
IV C– Iso or hypo
CE T1WI, contrast-enhanced T1-weighted imaging; DWI, diffusion-weighted imaging; ADC, apparent diffusion coefficient; eADC, exponential apparent diffusion
coefficient; C +, enhancing; C –, nonenhancing; hyper, hyperintense; iso, isointense; hypo, hypointense; T2 T-S, T2-shine through effect.
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according to their signal intensity on CE T1WI and DWI.
Type I lesions were enhancing on CE T1WI and hyperin-
tense on DWI. Type II lesions were enhancing on CE
T1WI and nonhyperintense (isointense or hypointense)
on DWI. Type III lesions were nonenhancing on CE
T1WI and hyperintense on DWI. Type IV lesions were
nonenhancing on CE T1WI and nonhyperintense on
DWI. Each type was further divided into two subtypes
according to the DWI, ADC and eADC. Subtype A lesions
showed restricted water diffusion as hyperintense on
DWI, hypointense on ADC and hyperintense on eADC.
Subtype B lesions showed non-restricted water diffusion
as iso- or hyperintense on ADC and iso- or hypointense
on eADC. The DWI signal in subtype B lesions may be
affected by the molecular motion of water and T2 shine-
through effect and thus may be variable. The classification
of the lesion types is summarized in Table 1. The foci on
CE T1WI (either enhancing or nonenhancing) were taken
as the gold standard for the diagnosis, and the signal in-
tensity (hyperintense or nonhyperintense) of each lesion
on DWI was compared to the status of enhancement on
CE T1WI.
Statistics
Fisher’s exact test was carried out to determine whether
the hyperintensity of the lesions on DWI was related to
contrast enhancement on CE T1WI. Significance was set
at a P value of less than 0.05. The sensitivity, specificity,
positive predictive value (PPV), negative predictive valueFigure 1 A type IA lesion in a patient with MS. (A) Axial T2-FLAIR brain
white matter (arrows). (B) CE T1WI shows a small central nodular enhancem
(arrow) is hyperintense on the DWI, hypointense on the ADC map, and hyp
with restricted water diffusion (cytotoxic edema).(NPV), and accuracy of the DWI for prediction of the
enhancement of demyelinating lesions on CE T1WI
were also calculated. The patient numbers fulfilling DIT
using CE T1WI or DWI were also calculated.
Results
A total of 22 patients (M/F = 5/17) with CDMS ranging
in age from 15 to 50 years (mean: 32.8 years, standard
deviation: 10.2) fulfilled the inclusion criteria. The 22 pa-
tients had converted to CDMS with intervals ranging
from 2 to 24 months after the onset of initial clinical
events (mean: 8.5 months, standard deviation: 5.2). The
patients’ average baseline expanded disability status scale
(EDSS) was 2.7 (range: 1.0-5.0, standard deviation: 1.2).
The interval between symptoms onset and baseline brain
MRI examinations ranged from 1 to 44 days (mean:
18 days, standard deviation: 10.7). The 22 brain MRI ex-
aminations disclosed a total of 384 demyelinating lesions
(51 enhancing and 333 nonenhancing) more than 3 mm
in size on T2WI and T2-FLAIR (range: 1–78, mean:
17.5, standard deviation: 17.4).
Ten patients (10/22 = 45.5%) showed simultaneously
asymptomatic enhancing and nonenhancing lesions on
CE T1WI while 12 patients did not (mean enhancing
lesions: 2.3 per person). All of the 51 enhancing lesions
were hyperintense on DWI (type I lesion). Of the 51 en-
hancing lesions, one was hypointense on the ADC map
and hyperintense on the eADC map (type IA lesion;
Figure 1), while the other 50 lesions were isointense
to hyperintense on the ADC map and isointense toMRI shows several demyelinating lesions in the bilateral periventricular
ent in one of the lesions on the right side (arrow). (C–E) The lesion
erintense on the eADC map, indicating an early stage of inflammation
Figure 2 A type IB lesion in a patient with MS. (A) Axial T2-FLAIR brain MRI shows dirty appearance of the bilateral periventricular white
matter and a demyelinating lesion on the left side (arrow). (B) The lesion (arrow) shows enhancement on the CE T1WI. (C–E) It is hyperintense on
the DWI, isointense to slightly hyperintense on the ADC map and isointense to slightly hypointense on the eADC map. The appearances suggest
an active stage of demyelination with conversion to vasogenic edema and the T2 shine-through effect.
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Among the 333 nonenhancing lesions, 107 were hyperin-
tense on DWI, iso- or hyperintense on the ADC map, and
iso- or hypointense on the eADC map (type IIIB lesion;
Figure 3), and 226 were nonhyperintense on DWI, iso- or
hyperintense on the ADC map, and iso or hypointense on
the eADC map (type IVB lesion; Figure 4). There were no
type II, IIIA and IVA lesions. The results are summarized
in Table 2. Hyperintensity on DWI was significantly linked
to contrast enhancement on CE T1WI (P <0.001). The
sensitivity, specificity, PPV, NPV, and accuracy for DWI to
predict the enhancement of the demyelinating lesions on
CE T1WI were 100%, 67.9%, 32.3%, 100%, and 72.1%,
respectively.
Simultaneously asymptomatic enhancing and none-
nhancing lesions (i.e. DIT) were present in 10 patients
(45.5%) on CE T1WI while simultaneously hyperintense
and nonhyperintense lesions were present in 12 patients
(54.4%) on DWI (Table 3). In addition, the distribution
of the demyelinating lesions in the aforementioned
patients also met the MRI DIS criteria in 9 patients
(40.9%) using CE T1WI and in 11 patients (50.0%) using
DWI, respectively. Retrospectively, MS could be early
diagnosed at CIS stage according to the 2010 RevisionsFigure 3 A type IIIB lesion in a patient with MS. (A) Axial T2-FLAIR brain
periventricular white matter and one in the right subcortical white matter.
one lesion involving the right periventricular white matter (arrow). (C–E) Th
map, and hypointense on the eADC map, indicating residual vasogenic ed
disappeared on follow-up MRI three months later (not shown).to the McDonald Criteria in 40.9% patients using CE
T1WI (and in 50.0% patients if DWI was used).
Discussion
MS is a chronic demyelinating disease of the CNS that
usually has a relapsing-remitting course, and the hetero-
geneity of disease activity may be reflected in the clinical
course, the immunopathological pattern as well as imaging
appearance. Actually different stages of the disease process
may be superimposed. The currently used McDonald
Criteria require demonstration of dissemination of CNS
demyelinating lesions in space and time, and the DIT cri-
terion of the 2010 version can be fulfilled by a single MRI
showing the simultaneous presence of asymptomatic
gadolinium-enhancing and nonenhancing lesions in a pa-
tient at CIS stage. CE T1WI can distinguish active from
inactive lesions in the brain since enhancement (cor-
responding to areas of active inflammation) occurs as a
result of increased BBB permeability. One of the questions
in the 2010 version of MRI DIT criterion is that the sen-
sitivity is relatively low due to fewer asymptomatic enhan-
cing brain lesions on a single baseline MRI. A Spanish
cohort study revealed a 52.63% sensitivity [7] and our
present study revealed that 45.5% patients fulfilled thisMRI shows multiple demyelinating lesions (arrows) in the bilateral
(B) All of the lesions show no enhancement on the CE T1WI, including
e lesion (arrow) is hyperintense on the DWI, hyperintense on the ADC
ema and the T2 shine-through effect. The hyperintensity on the DWI
Figure 4 Type IVB lesions in a patient with MS. (A) Axial T2-FLAIR brain MRI shows multiple demyelinating lesions in the bilateral periventricular
white matter. (B) All of the lesions show no enhancement on the CE T1WI. (C–E) Two of the lesions (arrows) in the posterior periventricular white
matter are hypointense on the DWI, hyperintense on the ADC map, and hypointense on the eADC map, indicating chronic lesions with increased
water diffusion due to severe tissue destruction.
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sequence to demonstrate DIT may be needed for possible
early diagnosis of MS.
The contrast provided by DWI (unlike CE T1WI) de-
pends on the molecular motion of water. Our study shows
that enhancing lesions all have abnormal hyperintensity
on DWI (100% sensitivity and 100% NPV) and type II
lesion (enhancing on CE T1WI and nonhyperintense on
DWI) is not found. However, many false positive type III
lesions on DWI were not enhanced on CE T1WI. There
are two possible reasons. First, the hyperintensity due to
alterations of water diffusion in the lesions is more sen-
sitive and lasts longer (may persist several months) than
lesion enhancement due to transient BBB disruption
(which usually lasts 4–6 weeks) [8-10]. Secondly, the high
signal intensity of some lesions on DWI may be attributed
to the “T2 shine-through” effect. The signal intensity on
DWI is influenced by water diffusivity and the intrinsic T2
properties of the tissue being examined. The increased
water content in demyelinating lesions may cause pro-
longation of T2 relaxation time and high signal on T2WI
and thus, hyperintensity on DWI [9]. To remove the
T2 shine-through effect, echo-planar spin echo T2WI
(b = 0 sec/mm2) can be used to obtain an eADC map from
DWI images. Our study shows that the T2 shine-through
effect mainly exists in type IB and type IIIB lesions with
hyperintensity on the DWI and hypointensity on the
eADC map.
There were three imaging patterns of demyelinating
lesions in our study. Type I lesions showed enhancement
on CE T1WI that suggests active perivascular inflam-
mation and BBB damage. Most active lesions have ele-
vated diffusion resulting from disruption of myelin and
increased extracellular space (vasogenic) edema (type IB)Table 2 The numbers of 384 demyelinating lesions in
each lesion type
Lesion type IA IB IIA IIB IIIA IIIB IVA IVB
Lesion numbers 1 50 0 0 0 107 0 226[11-13]. In rare instances, active lesions may reveal re-
stricted diffusion with cytotoxic edema mimicking the
radiological features of acute stroke (reduced ADC; type
IA). It is likely to be an early stage of inflammation. The
possible mechanisms of reduced ADC include infiltration
of inflammatory cells (mainly T-lymphocytes and macro-
phages/microglial cells) and associated macromolecules as
well as cytotoxic cell swelling, leading to reduced extra-
cellular space [8-11,13-17]. The reduced ADC signal may
take one to two weeks to revert to normal or increased
signal [10,16,17]. CE T1WI may help to differentiate
this early stage of demyelination from acute ischemic
infarction because active demyelinating lesions usually
enhance while acute ischemic infarcts do not [17]. In a
recent study of DWI in 42 cases of atypical indiopathic
inflammatory demyelinating lesions, restricted diffusion
with low ADC values were seen in the outer enhancing
part of the ring-like lesions, along the concentric rings of
Balo-like lesions, and at the enhancing periphery of the
infiltrative-type lesions, which corresponds to the areas of
active inflammatory and demyelinating activities [18]. The
lack of enhancement on CE T1WI in type IIIB lesions is
likely due to recovery of the BBB. However, the persistent
hyperintensity on DWI may suggest residual extracellular
edema with increased diffusion, prolongation of T2 rela-
xation time, and the T2 shine-through effect. Type IVB le-
sions show elevated diffusion and no enhancement on CE
T1WI that may be due to axonal loss and gliosis with
widening of the extracellular space. They may even form
“T1 black holes” on MRI, representing irreversible tissue
destruction [10-12,14,19,20].
The limitations of this study are as follows: (1) The
spatial resolution and signal-to-noise ratio of DWI wereTable 3 Patients fulfilling MRI DIT criteria
Used MRI sequence Patient numbers
CE T1WI 10 (45.5%)
DWI 12 (54.4%)
DIT, dissemination in time; CE T1WI, contrast-enhanced T1-weighted imaging;
DWI, diffusion-weighted imaging.
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had to exclude demyelinating lesions smaller than 3 mm
in size. (2) Spinal cord lesions were not included in the
study because DWI was not routinely used to evaluate the
spinal cord in our study population. The magnetic field in-
homogeneity around the spine, the small cross-sectional
size of the spinal cord, and the increased motion in that
area due to breathing, swallowing, and cerebrospinal fluid
pulsation also limited its use. (3) The histopathology of
different imaging types of demyelinating lesions was
derived from previous studies (brain biopsy and autopsy
evidence), and direct tissue proof was not obtained in our
study. (4) The study was a retrospective one, and the
interval between symptom onset and MRI studies varied
(range: 1–44 days) and so may have influenced the results.
A previous study showed that a better diagnostic per-
formance for demonstration of simultaneous presence
of gadolinium-enhancing and nonenhancing lesions was
achieved when MRI was obtained within the first 30 days
after symptom onset [4]. (5) The case number is relatively
small.
Conclusion
Our study have shown that lesion hyperintensity on DWI
is significantly related to lesion enhancement on CE
T1WI. We also delineated four types of demyelinating
lesions (type IA, IB, IIIB and IVB) according to their status
of enhancement on CE T1WI and signal intensity on
DWI. Although DWI may not replace CE T1WI (the
current gold standard) to demonstrate DIT because of the
many false positive lesions, it may serve as a screening
MRI sequence in cases where the use of GBCAs is a con-
cern for its high sensitivity (100%). Future studies with
tissue proof will be needed to prove if hyperintense and
nonhyperintense demyelinating lesions on DWI could
represent lesions in different stages of evolution (i.e. DIT).
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